New treatments in development for Pseudomonas aeruginosa infections in the lungs of individuals with cystic fibrosis

References

• Lipuma JJ. The changing microbial epidemiology in cystic fibrosis. Clin Microbiol Rev. 2010;23(2):299–323.
   PubMed Web of Science ®Google Scholar
• Grosse SD, Boyle CA, Botkin JR, et al. Newborn screening for cystic fibrosis: evaluation of benefits and risks and recommendations for state newborn screening programs. MMWR Recomm Rep. 2004;53(RR-13):1–36.
   Google Scholar
• Southern KW, Munck A, Pollitt R, et al. A survey of newborn screening for cystic fibrosis in Europe. J Cyst Fibros. 2007;6(1):57–65.
   PubMed Web of Science ®Google Scholar
• Kumar V, Abbas AK, Fausto N, Mitchell RS. Robbins Basic Pathology. 8th ed. Philadelphia: Elsevier; 2007.
   Google Scholar
• Bobadilla JL, Macek M Jr, Fine JP, Farrell PM. Cystic fibrosis: a worldwide analysis of CFTR mutations – correlation with incidence data and application to screening. Hum Mutat. 2002;19(6):575–606.
   PubMed Web of Science ®Google Scholar
• Roomans GM. Pharmacological treatment of the basic defect in cystic fibrosis. Cell Biol Int. Epub May 8, 2014.
   Google Scholar
• Sheppard DN, Welsh MJ. Structure and function of the CFTR chloride channel. Physiol Rev. 1999;79(Suppl 1):S23–S45.
   Google Scholar
• Mehta A. CFTR: more than just a chloride channel. Pediatr Pulmonol. 2005;39(4):292–298.
   PubMed Web of Science ®Google Scholar
• Quinton PM. Cystic fibrosis: impaired bicarbonate secretion and mucoviscidosis. Lancet. 2008;372(9636):415–417.
   PubMed Web of Science ®Google Scholar
• Reisin IL, Prat AG, Abraham EH, et al. The cystic fibrosis transmembrane conductance regulator is a dual ATP and chloride channel. J Biol Chem. 1994;269(32):20584–20591.
   Web of Science ®Google Scholar
• Schwiebert EM, Egan ME, Hwang TH, et al. CFTR regulates outwardly rectifying chloride channels through an autocrine mechanism involving ATP. Cell. 1995;81(7):1063–1073.
   Web of Science ®Google Scholar
• Stutts MJ, Canessa CM, Olsen JC, et al. CFTR as a cAMP-dependent regulator of sodium channels. Science. 1995;269(5225):847–850.
   PubMed Web of Science ®Google Scholar
• Vankeerberghen A, Cuppens H, Cassiman JJ. The cystic fibrosis transmembrane conductance regulator: an intriguing protein with pleiotropic functions. J Cyst Fibros. 2002;1(1):13–29.
   PubMedGoogle Scholar
• Matsui H, Grubb BR, Tarran R, et al. Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease. Cell. 1998;95(7):1005–1015.
   PubMed Web of Science ®Google Scholar
• Boucher RC. Airway surface dehydration in cystic fibrosis: pathogenesis and therapy. Annu Rev Med. 2007;58:157–170.
   PubMed Web of Science ®Google Scholar
• Matsui H, Wagner VE, Hill DB, et al. A physical linkage between cystic fibrosis airway surface dehydration and Pseudomonas aeruginosa biofilms. Proc Natl Acad Sci U S A. 2006;103(48):18131–18136.
   PubMed Web of Science ®Google Scholar
• Lethem MI, James SL, Marriott C. The role of mucous glycoproteins in the rheologic properties of cystic fibrosis sputum. Am Rev Respir Dis. 1990;142(5):1053–1058.
   Google Scholar
• Smith JJ, Travis SM, Greenberg EP, Welsh MJ. Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid. Cell. 1996;85(2):229–236.
   PubMed Web of Science ®Google Scholar
• Zabner J, Smith JJ, Karp PH, Widdicombe JH, Welsh MJ. Loss of CFTR chloride channels alters salt absorption by cystic fibrosis airway epithelia in vitro. Mol Cell. 1998;2(3):397–403.
   Web of Science ®Google Scholar
• Goldman MJ, Anderson GM, Stolzenberg ED, Kari UP, Zasloff M, Wilson JM. Human β-defensin-1 is a salt-sensitive antibiotic in lung that is inactivated in cystic fibrosis. Cell. 1997;88(4):553–560.
   PubMed Web of Science ®Google Scholar
• Pezzulo AA, Tang XX, Hoegger MJ, et al. Reduced airway surface pH impairs bacterial killing in the porcine cystic fibrosis lung. Nature. 2012;487(7405):109–113.
   PubMed Web of Science ®Google Scholar
• Ratner D, Mueller C. Immune responses in cystic fibrosis: are they intrinsically defective? Am J Respir Cell Mol Biol. 2012;46(6):715–722.
   Web of Science ®Google Scholar
• Bayes HK, Bicknell S, MacGregor G, Evans TJ. T helper cell subsets specific for Pseudomonas aeruginosa in healthy individuals and patients with cystic fibrosis. PLoS One. 2014;9(2):e90263.
   PubMed Web of Science ®Google Scholar
• Lyczak JB, Cannon CL, Pier GB. Lung infections associated with cystic fibrosis. Clin Microbiol Rev. 2002;15(2):194–222.
   PubMed Web of Science ®Google Scholar
• Lyczak JB, Cannon CL, Pier GB. Establishment of Pseudomonas aeruginosa infection: lessons from a versatile opportunist. Microbes Infect. 2000;2(9):1051–1060.
   PubMed Web of Science ®Google Scholar
• Harrison F. Microbial ecology of the cystic fibrosis lung. Microbiology. 2007;153(Pt 4):917–923.
   PubMedGoogle Scholar
• Donlan RM, Costerton JW. Biofilms: survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev. 2002;15(2):167–193.
   PubMed Web of Science ®Google Scholar
• Costerton JW, Lewandowski Z, Caldwell DE, Korber DR, Lappin-Scott HM. Microbial biofilms. Annu Rev Microbiol. 1995;49:711–745.
   PubMed Web of Science ®Google Scholar
• Worlitzsch D, Tarran R, Ulrich M, et al. Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients. J Clin Invest. 2002;109(3):317–325.
   PubMed Web of Science ®Google Scholar
• Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med. 2003;168(8):918–951.
   PubMed Web of Science ®Google Scholar
• Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. Science. 1999;284(5418):1318–1322.
   PubMed Web of Science ®Google Scholar
• Romling U, Fiedler B, Bosshammer J, et al. Epidemiology of chronic Pseudomonas aeruginosa infections in cystic fibrosis. J Infect Dis. 1994;170(6):1616–1621.
   Web of Science ®Google Scholar
• Høiby N, Bjarnsholt T, Givskov M, Molin S, Ciofu O. Antibiotic resistance of bacterial biofilms. Int J Antimicrob Agents. 2010;35(4):322–332.
   PubMed Web of Science ®Google Scholar
• Mogayzel PJ Jr, Naureckas ET, Robinson KA, et al. Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. Am J Respir Crit Care Med. 2013;187(7):680–689.
   PubMed Web of Science ®Google Scholar
• Høiby N. Recent advances in the treatment of Pseudomonas aeruginosa infections in cystic fibrosis. BMC Med. 2011;9:32.
   PubMed Web of Science ®Google Scholar
• Vakulenko SB, Mobashery S. Versatility of aminoglycosides and prospects for their future. Clin Microbiol Rev. 2003;16(3):430–450.
   PubMed Web of Science ®Google Scholar
• Bryan LE, Haraphongse R, Van den Elzen HM. Gentamicin resistance in clinical-isolates of Pseudomonas aeruginosa associated with diminished gentamicin accumulation and no detectable enzymatic modification. J Antibiot (Tokyo). 1976;29(7):743–753.
   Web of Science ®Google Scholar
• Hooper DC. Emerging mechanisms of fluoroquinolone resistance. Emerg Infect Dis. 2001;7(2):337–341.
   PubMed Web of Science ®Google Scholar
• Nordmann P, Guibert M. Extended-spectrum beta-lactamases in Pseudomonas aeruginosa. J Antimicrob Chemother. 1998;42(2):128–131.
   PubMed Web of Science ®Google Scholar
• Chen HY, Yuan M, Livermore DM. Mechanisms of resistance to beta-lactam antibiotics amongst Pseudomonas aeruginosa isolates collected in the UK in 1993. J Med Microbiol. 1995;43(4):300–309.
   Web of Science ®Google Scholar
• Strateva T, Yordanov D. Pseudomonas aeruginosa – a phenomenon of bacterial resistance. J Med Microbiol. 2009;58(Pt 9):1133–1148.
   PubMed Web of Science ®Google Scholar
• Starkey M, Hickman JH, Ma L, et al. Pseudomonas aeruginosa Rugose small-colony variants have adaptations that likely promote persistence in the cystic fibrosis lung. J Bacteriol. 2009;191(11):3492–3503.
   PubMed Web of Science ®Google Scholar
• Yahav D, Farbman L, Leibovici L, Paul M. Colistin: new lessons on an old antibiotic. Clin Microbiol Infect. 2012;18(1):18–29.
   PubMed Web of Science ®Google Scholar
• Bosso JA, Liptak CA, Seilheimer DK, Harrison GM. Toxicity of colistin in cystic fibrosis patients. DICP. 1991;25(11):1168–1170.
   PubMedGoogle Scholar
• Brown RB, Sands M, Morris AB. Seizure propensity with imipenem. Arch Intern Med. 1990;150(7):1551.
   Google Scholar
• Linden [webpage on the Internet]. Safety profile of meropenem: an updated review of over 6,000 patients treated with meropenem. Drug Saf. 2007;30(8):657–668.
   Web of Science ®Google Scholar
• Gilead Sciences. Phase 3 study of aztreonam for inhalation solution (AZLI) in a continuous alternating therapy regimen for the treatment of chronic Pseudomonas aeruginosa infection in patients with CF (AZLI CAT). Available from: http://clinicaltrials.gov/show/NCT01641822. NLM identifier:NCT01641822. Accessed August 21, 2014.
   Google Scholar
• Novartis Pharmaceuticals. Tobramycin inhalation powder (TIP) administered once daily continuously versus TIP administered BID in 28 day on/28 day off cycles. Available from: http://clinicaltrials.gov/show/NCT02015663. NLM identifier:NCT02015663. Accessed August 21, 2014.
   Google Scholar
• Döring G, Flume P, Heijerman H, Elborn JS Treatment of lung infection in patients with cystic fibrosis: current and future strategies. J Cyst Fibros. 2012;11(6):461–479.
   PubMed Web of Science ®Google Scholar
• Proesmans M, Vermeulen F, Boulanger L, Verhaegen J, De Boeck K. Comparison of two treatment regimens for eradication of Pseudomonas aeruginosa infection in children with cystic fibrosis. J Cyst Fibros. 2013;12(1):29–34.
   PubMed Web of Science ®Google Scholar
• Taccetti G, Bianchini E, Cariani L, et al. Early antibiotic treatment for Pseudomonas aeruginosa eradication in patients with cystic fibrosis: a randomised multicentre study comparing two different protocols. Thorax. 2012;67(10):853–859.
   PubMed Web of Science ®Google Scholar
• Milla CE, Chmiel JF, Accurso FJ, et al. Anti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection. Pediatr Pulmonol. 2014;49(7):650–658.
   PubMed Web of Science ®Google Scholar
• KaloBios Pharmaceuticals. Study to evaluate the effect of KB001-A on time-to-need for antibiotic treatment. Available from: http://clinicaltrials.gov/show/NCT01695343. NLM identifier: NCT01695343. Accessed August 21, 2014.
   Google Scholar
• Meers P, Neville M, Malinin V, et al. Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections. J Antimicrob Chemother. 2008;61(4):859–868.
   PubMed Web of Science ®Google Scholar
• Okusanya OO, Bhavnani SM, Hammel J, et al. Pharmacokinetic and pharmacodynamic evaluation of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonal infection. Antimicrob Agents Chemother. 2009;53(9):3847–3854.
   PubMed Web of Science ®Google Scholar
• Clancy JP, Dupont L, Konstan MW, et al. Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection. Thorax. 2013;68(9):818–825.
   PubMed Web of Science ®Google Scholar
• Bilton D, Pressler T, Isabelle F, et al. Phase 3 efficacy and safety data from randomized, multicenter study of liposomal amikacin for inhalation (Arikace) compared with TOBI® in cystic fibrosis patients with chronic infection due to Pseudomonas aeruginosa [abstract]. Pediatr Pulmonol. 2013;48(S36):290.
   Google Scholar
• CenterWatch. FDA lifts hold on Insmed’s Arikace. 2012. Available from: http://www.centerwatch.com/news-online/article/2785/fda-lifts-hold-on-insmeds-arikace#sthash.0ZMXjApN.dpbs. Accessed August 20, 2014.
   Google Scholar
• Kaneko Y, Thoendel M, Olakanmi O, Britigan BE, Singh PK. The transition metal gallium disrupts Pseudomonas aeruginosa iron metabolism and has antimicrobial and antibiofilm activity. J Clin Invest. 2007;117(4):877–888.
   PubMed Web of Science ®Google Scholar
• García-Contreras R, Peréz-Eretza B, Lira-Silva E, et al. Gallium induces the production of virulence factors in Pseudomonas aeruginosa. Pathog Dis. 2014;70(1):95–98.
   Web of Science ®Google Scholar
• Switzer B, Goss C, Abdalla M, Singh P, Britigan B. Gallium has potential as a new therapeutic agent for M. abscessus infections [abstract]. Pediatr Pulmonol. 2013;48(S36):334–335.
   Google Scholar
• Kakiuchi T, Pham B, Lechuga-Ballesteros D, Patzer EJ. Bactericidal activity of anti-infective panaecin™ (gallium nitrate) on antibiotic resistant P. aeruginosa from clinical isolates and in sputum from CF patients [abstract]. Pediatr Pulmonol. 2008;43(S31):318.
   Google Scholar
• Troung-Le V, Martin R, Ohtake S, Yee L, Patzer EJ, Lechuga-Ballesteros D. Intratracheal delivery of gallium results in higher local lung concentration and longer lung residence time compared to intravenous delivery in the rat [abstract]. Pediatr Pulmonol. 2009;44(S32):307–308.
   Google Scholar
• Yee L, Adamcakova-Dodd A, Binuraj A, et al. Pharmacokinetics, acute inhalation toxicity, and bacterial activities of anti-infective Panaecin™ (formulated gallium nitrate) [abstract]. Pediatr Pulmonol. 2010;45(S33):351.
   Google Scholar
• Halwani M, Yebio B, Suntres ZE, Alipour M, Azghani AO, Omri A. Co-encapsulation of gallium with gentamicin in liposomes enhances antimicrobial activity of gentamicin against Pseudomonas aeruginosa. J Antimicrob Chemother. 2008;62(6):1291–1297.
   PubMed Web of Science ®Google Scholar
• Goss CH, Hornick DB, Aitken ML, et al. Phase 1 pharmacokinetic and safety study of intravenous Ganite™ (gallium nitrate) in CF [abstract]. Pediatr Pulmonol. 2012;47(S35):303.
   Google Scholar
• Kollberg H, Carlander D, Olesen H, Wejåker PE, Johannesson M, Larsson A. Oral administration of specific yolk antibodies (IgY) may prevent Pseudomonas aeruginosa infections in patients with cystic fibrosis: a phase I feasibility study. Pediatr Pulmonol. 2003;35(6):433–440.
   PubMed Web of Science ®Google Scholar
• Nilsson E, Amini A, Wretlind B, Larsson A. Pseudomonas aeruginosa infections are prevented in cystic fibrosis patients by avian antibodies binding Pseudomonas aeruginosa flagellin. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;856(1–2):75–80.
   Web of Science ®Google Scholar
• Nilsson E, Kollberg H, Johannesson M, Wejåker PE, Carlander D, Larsson A. More than 10 years’ continuous oral treatment with specific immunoglobulin Y for the prevention of Pseudomonas aeruginosa infections: a case report. J Med Food. 2007;10(2):375–378.
   Web of Science ®Google Scholar
• Immunsystem. Anti-Pseudomonas IgY to prevent infections in cystic fibrosis (PseudIgY). Available from: http://clinicaltrials.gov/show/NCT00633191. NLM identifier:NCT00633191. Accessed August 21, 2014.
   Google Scholar
• Mukoviszidose Institut. Efficacy study of IgY (antibody against Pseudomonas) in cystic fibrosis patients (PsAer-IgY). Available from: http://clinicaltrials.gov/show/NCT01455675. NLM identifier:NCT01455675. Accessed August 21, 2014.
   Google Scholar
• Geller DE, Flume PA, Griffith DC, et al. Pharmacokinetics and safety of MP-376 (levofloxacin inhalation solution) in cystic fibrosis subjects. Antimicrob Agents Chemother. 2011;55(6):2636–2640.
   PubMed Web of Science ®Google Scholar
• Geller DE, Flume PA, Staab D, Fischer R, Loutit JS, Conrad DJ. Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa. Am J Respir Crit Care Med. 2011;183(11):1510–1516.
   PubMed Web of Science ®Google Scholar
• Mpex Pharmaceuticals. MP-376 (Aeroquin™, levofloxacin for inhalation) in patients with cystic fibrosis. Available from: http://clinicaltrials.gov/show/NCT01180634. NLM identifier:NCT01180634. Accessed August 21, 2014.
   Google Scholar
• Mpex Pharmaceuticals. Trial of aeroquin versus tobramycin inhalation solution (TIS) in cystic fibrosis (CF) patients. Available from: http://clinicaltrials.gov/show/NCT01270347. NLM identifier:NCT01270347. Accessed September 10, 2014.
   Google Scholar
• Stass H, Weimann B, Nagelschmitz J, Rolinck-Werninghaus C, Staab D. Tolerability and pharmacokinetic properties of ciprofloxacin dry powder for inhalation in patients with cystic fibrosis: a phase I, randomized, dose-escalation study. Clin Ther. 2013;35(10):1571–1581.
   PubMed Web of Science ®Google Scholar
• Stass H, Baumann-Noss S, Delesen H, et al. Pharmacokinetics of ciprofloxacin PulmoSphere inhalational powder. J Cyst Fibros. 2008;7:S26.
   Google Scholar
• Dorkin H, Criollo M, Reimnitz P, Alder J, Hampel B. Randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of inhaled ciprofloxacin compared with placebo in patients with cystic fibrosis – a phase IIB study of ciprofloxacin dry powder for inhalation (DPI) [abstract]. Pediatr Pulmonol. 2011;46(S43):296.
   Google Scholar
• Zhanel GG, Chung P, Adam H, et al. Ceftolozane/tazobactam: a novel cephalosporin/beta-lactamase inhibitor combination with activity against multidrug-resistant Gram-negative bacilli. Drugs. 2014;74(1):31–51.
   PubMed Web of Science ®Google Scholar
• Hoffman LR, D’Argenio DA, MacCoss MJ, Zhang Z, Jones RA, Miller SI. Aminoglycoside antibiotics induce bacterial biofilm formation. Nature. 2005;436(7054):1171–1175.
   PubMed Web of Science ®Google Scholar
• Linares JF, Gustafsson I, Baquero F, Martinez JL. Antibiotics as intermicrobial signaling agents instead of weapons. Proc Natl Acad Sci U S A. 2006;103(51):19484–19489.
   PubMed Web of Science ®Google Scholar
• Singh PK, Schaefer AL, Parsek MR, Moninger TO, Welsh MJ, Greenberg EP. Quorum-sensing signals indicate that cystic fibrosis lungs are infected with bacterial biofilms. Nature. 2000;407(6805):762–764.
   PubMed Web of Science ®Google Scholar
• Lai Y, Gallo RL. AMPed up immunity: how antimicrobial peptides have multiple roles in immune defense. Trends Immunol. 2009;30(3):131–141.
   PubMed Web of Science ®Google Scholar
• Zanetti M. Cathelicidins, multifunctional peptides of the innate immunity. J Leukoc Biol. 2004;75(1):39–48.
   PubMed Web of Science ®Google Scholar
• Kapoor R, Wadman MW, Dohm MT, Czyzewski AM, Spormann AM, Barron AE. Antimicrobial peptoids are effective against Pseudomonas aeruginosa biofilms. Antimicrob Agents Chemother. 2011;55(6):3054–3057.
   PubMed Web of Science ®Google Scholar
• Pompilio A, Scocchi M, Pomponio S, et al. Antibacterial and anti-biofilm effects of cathelicidin peptides against pathogens isolated from cystic fibrosis patients. Peptides. 2011;32(9):1807–1814.
   PubMed Web of Science ®Google Scholar
• Hancock RE, Sahl HG. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat Biotechnol. 2006;24(12):1551–1557.
   PubMed Web of Science ®Google Scholar
• Nagant C, Pitts B, Nazmi K, et al. Identification of peptides derived from the human antimicrobial peptide LL-37 active against biofilms formed by Pseudomonas aeruginosa using a library of truncated fragments. Antimicrob Agents Chemother. 2012;56(11):5698–5708.
   PubMed Web of Science ®Google Scholar
• Pompilio A, Crocetta V, Scocchi M, et al. Potential novel therapeutic strategies in cystic fibrosis: antimicrobial and anti-biofilm activity of natural and designed alpha-helical peptides against Staphylococcus aureus, Pseudomonas aeruginosa, and Stenotrophomonas maltophilia. BMC Microbiol. 2012;12:145.
   Google Scholar
• Hirt H, Gorr SU. Antimicrobial peptide GL13K is effective in reducing biofilms of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2013;57(10):4903–4910.
   PubMed Web of Science ®Google Scholar
• de Kievit TR. Quorum sensing in Pseudomonas aeruginosa biofilms. Environ Microbiol. 2009;11(2):279–288.
   PubMed Web of Science ®Google Scholar
• Liu HB, Lee JH, Kim JS, Park S. Inhibitors of the Pseudomonas aeruginosa quorum-sensing regulator, QscR. Biotechnol Bioeng. 2010;106(1):119–126.
   PubMed Web of Science ®Google Scholar
• Zeng X, Liu X, Bian J, et al. Synergistic effect of 14-alpha-lipoyl andrographolide and various antibiotics on the formation of biofilms and production of exopolysaccharide and pyocyanin by Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2011;55(6):3015–3017.
   Web of Science ®Google Scholar
• Packiavathy IA, Agilandeswari P, Musthafa KS, Pandian SK, Ravi AV. Antibiofilm and quorum sensing inhibitory potential of Cuminum cyminum and its secondary metabolite methyl eugenol against Gram negative bacterial pathogens. Food Res Int. 2012;45(1):85–92.
   Web of Science ®Google Scholar
• Husain FM, Ahmad I, Asif M, Tahseen Q. Influence of clove oil on certain quorum-sensing-regulated functions and biofilm of Pseudomonas aeruginosa and Aeromonas hydrophila. J Biosci. 2013;38(5):835–844.
   Google Scholar
• Murugan K, Sangeetha S, Kalyanasundaram VB, Al-Sohaibani S. In vitro and in silico screening for Andrographis paniculata quorum sensing mimics: new therapeutic leads for cystic fibrosis Pseudomonas aeruginosa biofilms. Plant Omics. 2013;6(5):340–346.
   Web of Science ®Google Scholar
• Bjarnsholt T, Jensen PØ, Rasmussen TB, et al. Garlic blocks quorum sensing and promotes rapid clearing of pulmonary Pseudomonas aeruginosa infections. Microbiology. 2005;151(Pt 12):3873–3880.
   PubMedGoogle Scholar
• O’Loughlin CT, Miller LC, Siryaporn A, Drescher K, Semmelhack MF, Bassler BL. A quorum-sensing inhibitor blocks Pseudomonas aeruginosa virulence and biofilm formation. Proc Natl Acad Sci U S A. 2013;110(44):17981–17986.
   PubMed Web of Science ®Google Scholar
• Lu Q, Yu J, Yang X, et al. Ambroxol interferes with Pseudomonas aeruginosa quorum sensing. Int J Antimicrob Agents. 2010;36(3):211–215.
   Web of Science ®Google Scholar
• AlgiPharma A phase IIB study of OligoG in subjects with cystic fibrosis (SMR-2984). Available from: http://clinicaltrials.gov/ct2/show/NCT02157922. NLM identifier:NCT02157922. Accessed August 21, 2014.
   Google Scholar
• Powell LC, Sowedan A, Khan S, et al. The effect of alginate oligosaccharides on the mechanical properties of Gram-negative biofilms. Biofouling. 2013;29(4):413–421.
   PubMed Web of Science ®Google Scholar
• Powell LC, Pritchard MF, Emanuel C, et al. A nanoscale characterization of the interaction of a novel alginate oligomer with the cell surface and motility of Pseudomonas aeruginosa. Am J Respir Cell Mol Biol. 2014;50(3):483–492.
   PubMed Web of Science ®Google Scholar
• Whitchurch CB, Tolker-Nielsen T, Ragas PC, Mattick JS. Extracellular DNA required for bacterial biofilm formation. Science. 2002;295(5559):1487.
   PubMed Web of Science ®Google Scholar
• Donnelly RF, McCarron PA, Cassidy CM, Elborn JS, Tunney MM. Delivery of photosensitisers and light through mucus: investigations into the potential use of photodynamic therapy for treatment of Pseudomonas aeruginosa cystic fibrosis pulmonary infection. J Control Release. 2007;117(2):217–226.
   PubMed Web of Science ®Google Scholar